Skip to content

A randomized, subject-blinded evaluation of visual function after bilateral implantation of two types of presbyopia-correcting multifocal IOLs.

A randomized, subject-blinded evaluation of visual function after bilateral implantation of two types of presbyopia-correcting multifocal IOLs.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON28310
Enrollment
28
Registered
2012-08-02
Start date
2012-08-15
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Correction of presbyopia after cataract surgery by multifocal intraocular lenses (IOLs) Correctie van presbyopie (ouderdomsverziendheid) na een cataractoperatie (staaroperatie) met intraoculaire implantlenzen (IOLs)

Interventions

Cataract extraction in both eyes with implantation of a multifocal intraocular lens (the multifocal FineVision Micro F IOL or the multifocal AcrySof® IQ ReSTOR® +3 IOL).

Sponsors

University Eye Clinic Maastricht, The Netherlands
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Bilateral cataract; 2. Less than 1.00 diopters of corneal astigmatism in both eyes; 3. Fulfill the recommendations in the “Warnings” and “Precautions” sections of the AcrySof ReSTOR and FineVision package inserts*; 4. Age 42 years or older; 5. Expected postoperative best-corrected visual acuity of logMAR +0.3 or better; 6. Availability to undergo second eye surgery within 2 weeks of the first eye surgery; 7. Willing and able to comply with scheduled visits and other study procedures; 8. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Planned multiple procedures, including LRI, during cataract/IOL implantation surgery; 2. Previous corneal surgery and/or reshaping; 3. Clinically significant corneal endothelial dystrophy (e.g., Fuchs’ dystrophy); 4. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, etc.); 5. Extensive age related macular degeneration (atrophic or exudative age-related macular degeneration or numerous soft drusen); 6. Glaucoma related extensive visual field loss; 7. Extensive diabetic macular disease; 8. Suturing of incision required at time of surgery; 9. Complications during surgery of the first eye.

Design outcomes

Primary

MeasureTime frame
Primary outcome measure is the mean bilateral DCVA at intermediate distance (70cm) under mesopic conditions at 1, 3 and 6 months postoperatively.

Secondary

MeasureTime frame
Secondary outcome measures are: 1. Mean unilateral UCVA at near (40cm), intermediate (70cm) and distance (4m) at photopic and mesopic conditions at 1, 3 and 6 months postoperatively; 2. Mean bilateral UCVA at near (40cm), intermediate (70cm) and distance (4m) at photopic and mesopic conditions at 1, 3 and 6 months postoperatively; 3. Mean unilateral DCVA at near (40cm), intermediate (70cm) and distance (4m) at photopic and mesopic conditions at 1, 3 and 6 months postoperatively; 4. Mean bilateral DCVA at near (40cm), intermediate (70cm) and distance (4m) at photopic conditions and mean bilateral DCVA at near (40cm) and distance (4m) at mesopic conditions at 1, 3 and 6 months postoperatively; 5. Mean contrast sensitivity monocular and binocular at photopic and mesopic conditions at 1, 3 and 6 months postoperatively; 6. Reading speed at photopic and mesopic conditions at 6 months postoperatively; 7. Mean vision-specific quality of life at 6 months postoperatively. Furthermore, adverse events, including complications, will be reported for each patient.

Contacts

Public ContactFrank Biggelaar, van den

PO Box 5800

f.vanden.biggelaar@mumc.nl+31 (0)43 3877377

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)